Recursion Pharmaceuticals Inc - Class A
Research Recursion Pharmaceuticals Inc - Class A (RXRX) on Bullrun: market cap USD 1.90B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRXRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.90B
- Financial periodQ2 2026
- RevenueUSD 7.30M
- Net income-USD 131.01M
- Free cash flow-USD 107.91M
- Gross margin-57.3%
Valuation Snapshot
latest market cap is USD 1.90B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 74.68M | -USD 644.76M | -USD 378.28M | 5.0% | -1.44 | USD 743.29M | USD 77.97M | USD 1.13B |
| FY2024 | USD 58.84M | -USD 463.66M | -USD 372.87M | 23.1% | -1.69 | USD 594.35M | USD 108.49M | USD 1.03B |
| FY2023 | USD 44.58M | -USD 328.07M | -USD 299.74M | 4.5% | -1.58 | USD 391.57M | USD 50.67M | USD 463.44M |
| FY2022 | USD 39.84M | -USD 239.48M | -USD 120.58M | -21.2% | -1.36 | USD 549.91M | USD 53.68M | USD 485.81M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.90B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.16B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.68B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.13B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.46B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.92B | n/a | n/a | n/a |
About Recursion Pharmaceuticals Inc - Class A
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Recursion Pharmaceuticals Inc - Class A's market cap?
Recursion Pharmaceuticals Inc - Class A's market capitalization is USD 1.90B.
What does Recursion Pharmaceuticals Inc - Class A do?
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.